Saturday, October 31, 2026

Strategic Partnerships

1 article

NVIDIA Locks In Dual Pharma Deals With Eli Lilly and Thermo Fisher, Making BioNeMo Drug Discovery's Core AI Layer

NVIDIA secured simultaneous partnerships with Eli Lilly and Thermo Fisher in January 2026, anchoring BioNeMo as the foundational AI infrastructure for pharmaceutical research. The deals triggered a wave of AI foundation model launches from specialized biotech firms including Basecamp Research, Boltz, Owkin, Edison Scientific, and Natera. The dynamic mirrors cloud infrastructure consolidation — one dominant platform enabling a specialized application ecosystem above it.

LM Salvado•May 1, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings

ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,995

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,995 facts checked against source5,525 source documents archived

Query this data → isubstrate.com